持股变动声明
EyePoint(EYPT)02-14 06:45
$EyePoint(EYPT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-24-001294 Size: 33 KB 网页链接
简介:EyePoint Pharmaceuticals Inc.于2008年3月成为特拉华州公司。其前身,pSivida有限公司于2000年12月在西澳大利亚注册成立一家澳大利亚公司。 pSivida开发微小,缓释,药物输送的产品。该公司用于药物输送的产品,依其设计,几个月或几年中都可控制和稳定输送药物速率。pSivida公司专注于利用其核心技术平台,Durasert和BioSilicon治疗眼睛后部的慢性疾病。 pSivida目前有三个认可的产品和两个主要正在开发的候选产品,这些产品代表了连续几代的Durasert技术平台。 pSivida公司开发的四分之三用于治疗视网膜疾病的缓释装置,目前已获得美国或欧洲联盟(欧盟)的批准。
今开:16.26 | 昨收:16.47 |
最高:16.26 | 最低:15.51 |
涨停价: | 跌停价: |
总市值:805265599 |
EyePoint(EYPT)02-14 06:45
$EyePoint(EYPT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-24-001294 Size: 33 KB 网页链接
EyePoint(EYPT)01-31 05:55
$EyePoint(EYPT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-24-000808 Size: 20 KB 网页链接
EyePoint(EYPT)03-05 06:45
$EyePoint(EYPT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-24-002119 Size: 5 KB 网页链接
EyePoint(EYPT)02-06 06:25
$EyePoint(EYPT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-24-001050 Size: 8 KB 网页链接
EyePoint(EYPT)03-04 20:05
$EyePoint(EYPT)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0000950170-24-024346 Act: 34 Size: 212 KB 网页链接
EyePoint(EYPT)03-07 20:15
$EyePoint(EYPT)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-24-027582 Act: 34 Size: 393 KB 网页链接
EyePoint(EYPT)02-14 06:45
$EyePoint(EYPT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-24-001292 Size: 14 KB 网页链接
EyePoint(EYPT)02-14 01:05
$EyePoint(EYPT)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000919574-24-000946 Act: 34 Size: 122 KB 网页链接
EyePoint(EYPT)01-30 06:55
$EyePoint(EYPT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-24-000785 Size: 15 KB 网页链接
EyePoint(EYPT)02-23 06:15
$EyePoint(EYPT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-24-001624 Size: 7 KB 网页链接
美股骑手01-23 12:02
JPM分析师给予$EyePoint(EYPT)$ EyePoint Pharmaceuticals首次覆盖,并给出增持评级,目标价35美元(较收盘价高45%)。
公司前景:
看好 EyePoint 公司的产品 EYP-1901,认为其在可持续释放领域的独特方法(通过眼底注射)构建了一个涉及多个适应症的产品管线。
阐述了 EyePoint 在湿...查看全文
童真的打新星光01-15 17:51
$EyePoint(EYPT)$ 好像二三季度要启动三期临床了吧?有知道时间节点的吗?查看全文
大won2023-12-14 18:13
回复@xiaomzho: 一邊賣EYEPOINT, 一邊囘購。這是上策。//@xiaomzho:回购开始了, 今天买了1.75万股, 距离1亿港币还差99.99%, 算是好的开始了$欧康维视生物-B(01477)$查看全文
锦瑟无端2023-12-05 18:27
$EyePoint(EYPT)$ 赶紧停牌,列入重点监控!查看全文
白沙君2023-12-05 10:05
回复@华阳_huayang0808: 这种相互授权合作,并不一定需要给很多钱,而且之前的公告也没提到销售分成和里程碑付款,贝达买的时候那个时候刚一期结束,数据没现在这么硬,而且还要一起开发临床。可惜的是贝达没有持股eyepoint,否则就凭这一个药,要是成了,eyepoint市值至少能翻十倍。//@华阳_huaya...查看全文
白沙君2023-12-05 09:58
回复@华阳_huayang0808: 不是合作,是大中华区独家授权。
5月4日,贝达药业与EyePoint Pharmaceuticals, Inc.(NASDAQ: EYPT,以下简称“EyePoint”)签署《扩大许可协议》,贝达药业将在大中华地区(包括香港、澳门和台湾)独家开发和销售EYP-1901,EyePoint负责 EYP-1901全球其他地区的商业...查看全文
同花顺(300033)金融研究中心5月16日讯,有投资者向贝达药业(300558)提问, 董秘您好,我看到贝达与EyePoint签订了有关EYP-1901的合作协议,想问下这款药物目前处于什么阶段?预计什么时候可以上市?是否会对公司经营产生影响? 公... 网页链接
国金证券05月08日发布研报称,维持贝达药业(300558.SZ,最新价:43.75元)买入评级。评级理由主要包括:1)再度携手Eyepoint,给药系统加持伏罗尼布,新型治疗方案值得期待;2)肺癌布局全面,核心产品市场地位维持,新药快速放量。风险提示... 网页链接
《电鳗快报》韩风/文 5月5日,贝达药业股份有限公司(以下简称“贝达药业”)发布了关于公司与EyePoint Pharmaceuticals, Inc.(NASDAQ: EYPT,以下简称“EyePoint”)签订EYP-1901合作协议的公告。公告内容显示,5月 4日,贝达药业与 EyePoint... 网页链接
5月5日,贝达药业发布公告,其与EyePoint Pharmaceuticals, Inc. ( 以下简称“EyePoint”)签署《扩大许可协议》,就EYP-1901在中国(包括香港、澳门和台湾)区域的开发和商业化进行独家合作。 根据《扩大许可协议》,贝达药业取得在中国(包... 网页链接
欧康维视生物-B(01477.HK)表示,公司从EyePoint公司授权引进的OT-401(YUTIQ,氟轻松玻璃体内植入剂)新药申请近日已获国家药品监督管理局受理,该药物亦为首款在中国内地提交新药申请的缓释微型植入剂,其在长达36个月内拥有经... 网页链接
格隆汇 1 月 4日丨 欧康维视生物-B(01477.HK)发布公告,2020年12月31日,公司与EyePoint(公司的许可方伙伴之一,其普通股股份以股份代号“EYPT”于纳斯达克交易)订立股份购买协议,据此,EyePoint已同意发行及出售,而公司已同意根据股份购买协议的条款及... 网页链接
$EyePoint(EYPT)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0000902664-24-003016 Size: 8 KB 网页链接
$EyePoint(EYPT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000929638-24-001536 Size: 11 KB 网页链接
$EyePoint(EYPT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-24-003193 Size: 19 KB 网页链接
$EyePoint(EYPT)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000950170-24-028523 Act: 34 Size: 12 MB 网页链接
$EyePoint(EYPT)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-24-027582 Act: 34 Size: 393 KB 网页链接
$EyePoint(EYPT)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001562180-24-002118 Size: 6 KB 网页链接
$EyePoint(EYPT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-24-002119 Size: 5 KB 网页链接
$EyePoint(EYPT)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0000950170-24-024346 Act: 34 Size: 212 KB 网页链接
$EyePoint(EYPT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-24-001895 Size: 7 KB 网页链接
$EyePoint(EYPT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001562180-24-001624 Size: 7 KB 网页链接